Literature DB >> 27401613

Transforming Big Data into Cancer-Relevant Insight: An Initial, Multi-Tier Approach to Assess Reproducibility and Relevance.

.   

Abstract

The Cancer Target Discovery and Development (CTD(2)) Network was established to accelerate the transformation of "Big Data" into novel pharmacologic targets, lead compounds, and biomarkers for rapid translation into improved patient outcomes. It rapidly became clear in this collaborative network that a key central issue was to define what constitutes sufficient computational or experimental evidence to support a biologically or clinically relevant finding. This article represents a first attempt to delineate the challenges of supporting and confirming discoveries arising from the systematic analysis of large-scale data resources in a collaborative work environment and to provide a framework that would begin a community discussion to resolve these challenges. The Network implemented a multi-tier framework designed to substantiate the biological and biomedical relevance as well as the reproducibility of data and insights resulting from its collaborative activities. The same approach can be used by the broad scientific community to drive development of novel therapeutic and biomarker strategies for cancer. Mol Cancer Res; 14(8); 675-82. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27401613      PMCID: PMC4987219          DOI: 10.1158/1541-7786.MCR-16-0090

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  20 in total

1.  Drug development: Raise standards for preclinical cancer research.

Authors:  C Glenn Begley; Lee M Ellis
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

2.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Functional kinomics identifies candidate therapeutic targets in head and neck cancer.

Authors:  Russell Moser; Chang Xu; Michael Kao; James Annis; Luisa Angelica Lerma; Christopher M Schaupp; Kay E Gurley; In Sock Jang; Asel Biktasova; Wendell G Yarbrough; Adam A Margolin; Carla Grandori; Christopher J Kemp; Eduardo Méndez
Journal:  Clin Cancer Res       Date:  2014-08-15       Impact factor: 12.531

4.  Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.

Authors:  Alvaro Aytes; Antonina Mitrofanova; Celine Lefebvre; Mariano J Alvarez; Mireia Castillo-Martin; Tian Zheng; James A Eastham; Anuradha Gopalan; Kenneth J Pienta; Michael M Shen; Andrea Califano; Cory Abate-Shen
Journal:  Cancer Cell       Date:  2014-05-12       Impact factor: 31.743

5.  ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state.

Authors:  Yakov Chudnovsky; Dohoon Kim; Siyuan Zheng; Warren A Whyte; Mukesh Bansal; Mark-Anthony Bray; Shuba Gopal; Matthew A Theisen; Steve Bilodeau; Prathapan Thiru; Julien Muffat; Omer H Yilmaz; Maya Mitalipova; Kevin Woolard; Jeongwu Lee; Riko Nishimura; Nobuo Sakata; Howard A Fine; Anne E Carpenter; Serena J Silver; Roel G W Verhaak; Andrea Califano; Richard A Young; Keith L Ligon; Ingo K Mellinghoff; David E Root; David M Sabatini; William C Hahn; Milan G Chheda
Journal:  Cell Rep       Date:  2014-01-16       Impact factor: 9.423

6.  IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.

Authors:  Xiaoduo Xie; Denghong Zhang; Bin Zhao; Min-Kan Lu; Ming You; Gianluigi Condorelli; Cun-Yu Wang; Kun-Liang Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-04       Impact factor: 11.205

7.  TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation.

Authors:  Yi-Hung Ou; Michael Torres; Rosalyn Ram; Etienne Formstecher; Christina Roland; Tzuling Cheng; Rolf Brekken; Ryan Wurz; Andrew Tasker; Tony Polverino; Seng-Lai Tan; Michael A White
Journal:  Mol Cell       Date:  2011-02-18       Impact factor: 17.970

8.  Inconsistency in large pharmacogenomic studies.

Authors:  Benjamin Haibe-Kains; Nehme El-Hachem; Nicolai Juul Birkbak; Andrew C Jin; Andrew H Beck; Hugo J W L Aerts; John Quackenbush
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

9.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors:  David A Barbie; Pablo Tamayo; Jesse S Boehm; So Young Kim; Susan E Moody; Ian F Dunn; Anna C Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M Chan; Martin L Sos; Kathrin Michel; Craig Mermel; Serena J Silver; Barbara A Weir; Jan H Reiling; Qing Sheng; Piyush B Gupta; Raymond C Wadlow; Hanh Le; Sebastian Hoersch; Ben S Wittner; Sridhar Ramaswamy; David M Livingston; David M Sabatini; Matthew Meyerson; Roman K Thomas; Eric S Lander; Jill P Mesirov; David E Root; D Gary Gilliland; Tyler Jacks; William C Hahn
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

10.  Why most published research findings are false.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2005-08-30       Impact factor: 11.613

View more
  5 in total

Review 1.  Personalized Cancer Models for Target Discovery and Precision Medicine.

Authors:  Carla Grandori; Christopher J Kemp
Journal:  Trends Cancer       Date:  2018-08-08

Review 2.  An expanded universe of cancer targets.

Authors:  William C Hahn; Joel S Bader; Theodore P Braun; Andrea Califano; Paul A Clemons; Brian J Druker; Andrew J Ewald; Haian Fu; Subhashini Jagu; Christopher J Kemp; William Kim; Calvin J Kuo; Michael McManus; Gordon B Mills; Xiulei Mo; Nidhi Sahni; Stuart L Schreiber; Jessica A Talamas; Pablo Tamayo; Jeffrey W Tyner; Bridget K Wagner; William A Weiss; Daniela S Gerhard
Journal:  Cell       Date:  2021-03-04       Impact factor: 41.582

3.  Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative.

Authors:  Hans R Hendriks; Anne-Sophie Govaerts; Iduna Fichtner; Sally Burtles; Andrew D Westwell; Godefridus J Peters
Journal:  Br J Cancer       Date:  2017-06-13       Impact factor: 7.640

4.  CTD2 Dashboard: a searchable web interface to connect validated results from the Cancer Target Discovery and Development Network.

Authors:  Bülent Arman Aksoy; Vlado Dancík; Kenneth Smith; Jessica N Mazerik; Zhou Ji; Benjamin Gross; Olga Nikolova; Nadia Jaber; Andrea Califano; Stuart L Schreiber; Daniela S Gerhard; Leandro C Hermida; Subhashini Jagu; Chris Sander; Aris Floratos; Paul A Clemons
Journal:  Database (Oxford)       Date:  2017-01-01       Impact factor: 3.451

5.  Human Disease Ontology 2018 update: classification, content and workflow expansion.

Authors:  Lynn M Schriml; Elvira Mitraka; James Munro; Becky Tauber; Mike Schor; Lance Nickle; Victor Felix; Linda Jeng; Cynthia Bearer; Richard Lichenstein; Katharine Bisordi; Nicole Campion; Brooke Hyman; David Kurland; Connor Patrick Oates; Siobhan Kibbey; Poorna Sreekumar; Chris Le; Michelle Giglio; Carol Greene
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.